首页 > 市场调查报告书 > 製药

癌症呼吸器

市场调查报告书

商品编码

1140730

全球鼻咽癌市场-2022-2029

Global Nasopharyngeal Cancer Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

提高对鼻咽癌的认识是市场增长的驱动力

对鼻咽癌诊治的认识不断提高。过去，由于政府力度不够，发病率相对较低，鼻咽癌在公众中并不为人所知，现在正在上升。因此，我们在多个基层医疗保健中心开展了提高对鼻咽癌认识的活动，针对易患鼻咽癌的人群。因此，鼻咽癌诊断和治疗的日益普及正在推动全球鼻咽癌市场的增长。

然而，鼻咽癌的高昂治疗费用对市场增长产生了负面影响。化疗、手术和放疗等高昂的治疗费用在没有保险的癌症患者中造成了自付费用。不断上涨的药品价格增加了治疗的整体经济负担。这可能是全球鼻咽癌治疗市场的障碍。鼻咽癌市场有很多优势，也有很多劣势。高昂的治疗成本和副作用是鼻咽癌市场的障碍。

地理渗透

亚太地区将是预测期内的主要地区。

该研究按地区分析了全球市场的动物干细胞治疗市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

预计亚太地区将在预测期内增长最快。鼻咽癌是亚太地区最常见的头颈部癌症之一。据说雄性比雌性更容易繁殖两到三倍。发病高峰在 50 至 60 岁之间。这种癌症常见于东南亚。此外，世界上鼻咽癌发病率最高的五个国家分别是印度尼西亚、中国、越南、印度和马来西亚。根据美国癌症协会发表的一项研究，中国部分地区每 10 万男性中高达 25-30 例，每 10 万女性中高达 15-20 例。由于鼻咽癌治疗和程序的便利性和可用性，发达地区对鼻咽癌市场的需求正在增加。公司正在大力投资发展中地区，以提供有效的治疗解决方案，以实现更高质量的护理、更高的效率和更好的患者治疗效果。此外，发展中地区对医疗保健意识的提高以及对 IT 和医疗保健技术的支出增加也有望推动鼻咽癌市场对有效治疗的总体需求。

竞争格局

由于主要竞争者的存在，鼻咽癌市场是一个竞争激烈的市场。市场上的一些主要关键参与者是 Bristol-Myers Squibb、Cyclacel Pharmaceuticals Inc.、Eli Lilly & Co.、GLAXOSMITHKLINE PLC、Merck & Co.、Novartis International AG、Ono Pharmaceutical Co., Ltd.、Safoni、Theravectysys、Merck &Co。 Safoni、Theravectis SA 等主要参与者正在为全球鼻咽癌市场的增长采用新产品发布或扩展策略。 2022 年 3 月，百时美施贵宝以每股 76 美元的价格收购了领先的精准肿瘤学公司 TurningPoint Therapeutics。此次收购将通过增加一流的晚期精准肿瘤学资产，帮助扩大公司领先的肿瘤学专营权。 2021 年 7 月，礼来公司宣布将以 10 亿美元收购推动 1 型糖尿病 (TD1) 治疗的私营生物技术公司 Promoter Technologies。此次收购将加速 T1D 患者的下一代、改变生活的治疗。 2021年4月，专注于罕见癌症靶向治疗的加州生物製药公司GLAXOSMITHKLINE PLC收购了Sierra Oncology；被收购。此次收购还包括莫莫替尼，这是一种具有独特双重作用机制的晚期候选药物，可以解决贫血性骨髓纤维化患者未满足的医疗需求。此次收购将有助于扩大我们创新的肿瘤学产品组合。

COVID-19 的影响将对全球鼻咽癌市场产生负面影响。

由于大流行期间医院就诊率和诊断率降低，COVID-19 大流行阻碍了鼻咽癌市场的增长。临床数据显示，癌症患者（其中许多是老年人和免疫抑制患者）更容易感染 COVID-19。在 COVID-19 大流行期间，在家中保持安全和增强免疫力已成为主要问题，导致 2020 年就诊次数减少和鼻咽癌市场低迷。

全球鼻咽癌市场报告提供大约 50 个市场数据表、42 个图表和 170 页内容

Market Overview

Nasopharyngeal Cancer Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.7 % during the forecast period (2022-2029).

Nasopharyngeal cancer is a rare therapy of malignant cancer that appears in the nasopharynx. It is the upper part of the throat behind the nose. The nasopharynx is situated at the base of the skull, directly above the roof of the mouth. Nasopharyngeal cancer generally starts in the squamous cells that track the nasopharynx. The exact sources of nasopharyngeal cancer are unknown; however, a few risk factors are linked with nasopharyngeal cancer. Exposure to the Epstein-Barr virus is deemed a common risk factor for nasopharyngeal cancer. Also, people of East Asian or Chinese ancestry are more prone to cancer. Early symptoms of nasopharyngeal cancer involve a sore throat, lump in the nose or neck, difficulty in breathing or speaking, difficulty in hearing, pain or ringing in the ear or headaches. The nasopharyngeal cancer market has grown significantly at a strong CAGR due to the increasing patient count with nasopharyngeal cancer. The nasopharyngeal cancer market will likely grow globally with technological advancement and innovation.

Market Dynamics: Increasing awareness regarding nasopharyngeal cancer drive market growth

There is a rising awareness of the diagnosis and treatment of nasopharyngeal cancer. Conventionally, the public perception concerning nasopharyngeal cancer was low due to the lack of government initiatives and the relatively low incidence rate of the disease. To boost community awareness for ethnicities prone to nasopharyngeal cancer, several primary healthcare centers have begun awareness campaigns to enhance the awareness of nasopharyngeal cancer. Therefore, greater adoption of nasopharyngeal cancer diagnosis and treatment is being witnessed, driving the growth of the global nasopharyngeal cancer market.

However, the High treatment cost of nasopharyngeal cancer negatively impacted the market growth. The high price of therapeutic procedures, such as chemotherapy, surgeries, and radiation therapy, results in out-of-pocket expenditure among non-insured cancer patients. The high price of drugs adds to the overarching financial burden of the treatment. It can act as a barrier to the global nasopharyngeal cancer treatment market. With so many advantages of the nasopharyngeal cancer market, it has a few disadvantages too. The high cost of the treatment and side effects are a barrier to the nasopharyngeal cancer market.

Market Segmentation: The cryosurgery devices segment will project the fastest growth in the market throughout the forecast period

Based on therapy, the nasopharyngeal cancer market has been classified into chemotherapy, immunotherapy, radiation therapy and others

Radiation Therapy is expected to hold a significant market share in the treatment therapy segment. Radiation therapy forms the main modality of treatment for nasopharyngeal cancer. Newer and advanced solutions for nasopharyngeal cancer treatment include a combination of both chemotherapy and radiotherapy techniques. These treatment modalities are at an early clinical phase and will make a commercial appearance late during the end of the forecast period.

Based on the End User, the animal stem cell therapy market has been classified into hospitals & clinics, ambulatory surgery centers and others

The hospitals & clinics segment is anticipated to hold the largest share in the global market. The rapid adoption of technologies is expected to boost the nasopharyngeal cancer treatment market. This trend is likely seen in emerging regions where healthcare expenditure is increasing considerably. Developed regions are observing that since the availability of nasopharyngeal cancer treatment and procedure is easily available, the demand for the nasopharyngeal cancer market has increased. Companies are investing heavily in emerging regions to offer efficient treatment solutions for higher healthcare quality, greater efficiency and better patient outcomes.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period.

Based on geography, the study analyzes the animal stem cell therapy market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

The Asia Pacific is expected to witness the fastest growth during the forecast period. In the Asia Pacific, nasopharyngeal cancer is one of the most widespread cancers in the head and neck areas. Men are two to three times more likely to grow it than women. The peak age of prevalence is between 50 and 60 years. This cancer is generally more common in Southeast Asia. Moreover, the five countries with the greatest incidence of nasopharyngeal cancer worldwide were Indonesia, China, Vietnam, India and Malaysia, respectively. According to the research published by the American Cancer Society, in some parts of China, there are as many as 25 to 30 cases per 100,000 men and 15 to 20 cases per 100,000 women. Developed regions are witnessing that since accessibility for nasopharyngeal cancer treatment and procedures are easily accessible and available, the demand for the nasopharyngeal cancer market has increased. Companies are investing heavily in developing regions to offer effective treatment solutions for higher care quality, greater efficiency and better patient outcomes. Moreover, increasing healthcare awareness, along with increasing spending on IT and healthcare technologies in developing regions, is expected to boost the overall demand for effective treatment in the nasopharyngeal cancer market.

Competitive Landscape:

The nasopharyngeal cancer market is highly competitive, owing to the presence of big competitive players in the market. Some major key players in the market are Bristol-Myers Squibb, Cyclacel Pharmaceuticals Inc., Eli Lilly And Co., GLAXOSMITHKLINE PLC, Merck & Co., Inc., Novartis International AG, ONO PHARMACEUTICAL CO. Safoni, Theravectys SA, among others. The major players are adopting new product launches and expansion strategies for global growth in the nasopharyngeal cancer market. In March 2022, Bristal Mayer Squibb acquired Turning Point Therapeutics, a Leading Precision Oncology Company, for $76.00 per Share. This acquisition helps to expand companies leading oncology franchise by adding a best-in-class, late-stage precision oncology asset. In July 2021, Eli Lilly announced the acquisition of promoter technologies, a private biotech company, to advance treatment for type 1 diabetes (TD1) for $1bn. This acquisition accelerates next-generation life-changing therapies for people living with T1D. In April 2021, GLAXOSMITHKLINE PLC, a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, acquired Sierra Oncology; a California based Biopharmaceutical Company focused on targeted therapies for the treatment of rare disease Cancer, for USD 1.9 Billion. This acquisition includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anemia. This acquisition helps to expand the innovative oncology portfolio.

COVID-19 Impact: Negative impact on the global nasopharyngeal cancer market.

The COVID-19 pandemic has hampered the growth of the nasopharyngeal cancer market, owing to the decline in hospital visits and the diagnosis rate of the disease amidst the pandemic. Cancer patients are predominantly elderly and immunosuppressed, and clinical data shows that they may be more susceptible to COVID-19 infection. The major concern during the COVID-19 pandemic was to stay safe at home and boost immunity, which has declined clinic visits, leading to the downfall in the nasopharyngeal cancer market in 2020.

The global nasopharyngeal cancer market report would provide an access to approximately 50 market data tables, 42 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Therapy
3.2. Market Snippet by End User
3.3. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing awareness regarding nasopharyngeal cancer
  - 4.1.1.2. Advancement in technology
- 4.1.2. Restraints:
  - 4.1.2.1. High treatment cost of nasopharyngeal cancer
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Therapy

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Segment
7.3. Market Attractiveness Index, By Therapy Segment
- 7.3.1. Chemotherpy*
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Immunotherapy
- 7.3.3. Radiation therapy
- 7.3.4. Others

8. By End User

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
8.3. Market Attractiveness Index, By End User Segment
- 8.3.1. Hospitals & Clinics*
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Ambulatory surgery centers Electronic
- 8.3.3. Others

9. By Region

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. U.S.
  - 9.4.5.2. Canada
  - 9.4.5.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. Germany
  - 9.5.5.2. U.K.
  - 9.5.5.3. France
  - 9.5.5.4. Italy
  - 9.5.5.5. Spain
  - 9.5.5.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.6.5.1. Brazil
  - 9.6.5.2. Argentina
  - 9.6.5.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.7.5.1. China
  - 9.7.5.2. India
  - 9.7.5.3. Japan
  - 9.7.5.4. Australia
  - 9.7.5.5. Rest of Asia Pacific
9.8. Middle East and Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
- 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Nasopharyngeal Cancer Market- Company Profiles

11.1. Bristol-Myers Squibb Co.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Biodiem Ltd.
11.3. Cyclacel Pharmaceuticals Inc.
11.4. Eli Lilly And Co.
11.5. GlaxoSmithKline Plc.
11.6. Merck & Co., Inc.
11.7. Novartis International AG
11.8. Ono Pharmaceutical Co.,
11.9. SafoniTheravectys SA (List Not Exhaustive)